FindTrial
Sign In

HEV vaccine

BIOLOGICAL2 trials

Sponsors

Xiamen University, Xiamen Innovax Biotech Co., Ltd

Conditions

Cervical CancerCervical Intraepithelial NeoplasiaHepatitis BHepatitis EPersistent InfectionVaginal Intraepithelial NeoplasiaVulvar Intraepithelial Neoplasia

Phase 3

Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine
CompletedNCT01735006
Xiamen UniversityCervical Cancer, Cervical Intraepithelial Neoplasia, Persistent Infection +2
Start: 2012-11-22End: 2019-10-18Updated: 2020-02-24

Phase 4

A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)
CompletedNCT02584543
Xiamen Innovax Biotech Co., LtdHepatitis B, Hepatitis E
Start: 2015-10-31End: 2016-08-25Updated: 2017-12-04

Related Papers

Variations in the Natural History of High-Risk HPV Types Following HPV-16/18 Bivalent Vaccination in Females Aged 18-45 Years.
2026-01-14
Immunopersistence of one or two doses of an Escherichia coli produced bivalent HPV vaccine.
2025-12-17
Long-term efficacy and immunopersistence of an <i>Escherichia coli</i>-produced HPV-16/18 bivalent vaccine: an observational extension study following a randomised, double-blind Phase III clinical trial cohort.
2025-08-21
Long-term protective efficacy of the <i>Escherichia coli-</i>produced HPV-16/18 bivalent human papillomavirus vaccine in women vaccinated at 18-45 years: A 9-year follow-up study.
2025-01-10
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial.
2022-08-2657 citations
Long-Term immunopersistence and safety of the <i>Escherichia coli</i> -produced HPV-16/18 bivalent vaccine in Chinese adolescent girls
Human Vaccines & Immunotherapeutics2022-04-135 citations